Carregant...
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
Glioblastoma is aggressive, highly infiltrating, and the most frequent malignant form of brain cancer. With a median survival time of only 14.6 months, when treated with the standard of care, it is essential to find new therapeutic options. A specific CDK4/6 inhibitor, PD0332991, obtained accelerate...
Guardat en:
| Publicat a: | Front Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4663246/ https://ncbi.nlm.nih.gov/pubmed/26649278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2015.00259 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|